Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4628 Triple negative breast neuroendocrine carcinoma in older patient: A rare entity

Introduction: Neuroendocrine breast carcinoma is a rare histological form of breast cancer, that represent 0.1% of all breast cancers and is recognised by the World Health Organization as a distinct entity. Characterised by a non-specific clinical and radiological presentation. Therapeutic management is not codified and is usually superimposed on that of classical breast cancer.

Conference:

Presenting Author:

Authors: Aris H, Saidi M, Lahfa I,

Keywords: neuroendocrine carcinoma, triple negative breast cancer, platinum-based combination therapy,

#2106 Long-Acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden

Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Berthon A

Authors: Berthon A, Björstad �, Granfeldt D, Marlow T, Dinét J,

Keywords: metastatic, GEP-NET, somatostatin analogues, treatment,

#2105 Long-Acting Somatostatin Analogue (LA-SSA) Treatment Durations in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden

Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Berthon A

Authors: Berthon A, Granfeldt D, Björstad A, Marlow T, Dinét J,

Keywords: metastatic, GEP-NET, somatostatin analogues, treatment,

#2104 Direct Cost of Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Relation to Time Since Diagnosis Shows Growing Importance of Somatostatin Analogues (SSA)

Introduction: Metastatic GEP-NET G1/G2 incurs large costs on the Swedish health care system.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Berthon A

Authors: Berthon A, Granfeldt D, Björstad A, Marlow T, Dinét J,

Keywords: metastatic, GEP-NET, cost-of-illness, somatostatin analogues,

#1648 Treatment Patterns and Survival Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden – A Population-Based Register-Linkage and Medical Chart Review Study

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is a group of neoplasms derived from the endocrine system in the GI tract and pancreas.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Johanson V

Authors: Lesén E, Granfeldt D, Houchard A, Berthon A, Dinet J,

Keywords: GEP-NET, SSA, treatment patterns, survival,